EP2371237B1 - Masque facial - Google Patents
Masque facial Download PDFInfo
- Publication number
- EP2371237B1 EP2371237B1 EP10158628.7A EP10158628A EP2371237B1 EP 2371237 B1 EP2371237 B1 EP 2371237B1 EP 10158628 A EP10158628 A EP 10158628A EP 2371237 B1 EP2371237 B1 EP 2371237B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- face mask
- segment
- face
- area
- cheek
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011282 treatment Methods 0.000 claims description 47
- 239000002537 cosmetic Substances 0.000 claims description 30
- 230000001815 facial effect Effects 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 19
- 230000006378 damage Effects 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 15
- 210000001061 forehead Anatomy 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 7
- 210000001331 nose Anatomy 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 210000000537 nasal bone Anatomy 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 description 30
- 208000027418 Wounds and injury Diseases 0.000 description 23
- 239000012876 carrier material Substances 0.000 description 23
- 239000004480 active ingredient Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- -1 dry or premoistened Substances 0.000 description 17
- 239000003921 oil Substances 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 17
- 239000003814 drug Substances 0.000 description 15
- 102000008186 Collagen Human genes 0.000 description 14
- 108010035532 Collagen Proteins 0.000 description 14
- 229920001436 collagen Polymers 0.000 description 14
- 239000000284 extract Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 208000014674 injury Diseases 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 206010052428 Wound Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 206010040954 Skin wrinkling Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000000419 plant extract Substances 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000037303 wrinkles Effects 0.000 description 7
- 238000001816 cooling Methods 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 5
- 229920005615 natural polymer Polymers 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 5
- 235000005493 rutin Nutrition 0.000 description 5
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 5
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 5
- 229960004555 rutoside Drugs 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- CGFPNELNAZZYQL-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;sulfuric acid Chemical class OS(O)(=O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CGFPNELNAZZYQL-RXSVEWSESA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- 230000006978 adaptation Effects 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical class OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 150000000996 L-ascorbic acids Chemical class 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 230000001055 chewing effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 159000000001 potassium salts Chemical class 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 240000000950 Hippophae rhamnoides Species 0.000 description 2
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 2
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 229940051879 analgesics and antipyretics salicylic acid and derivative Drugs 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229920003086 cellulose ether Polymers 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- 150000001783 ceramides Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 238000003475 lamination Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000002924 oxiranes Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 2
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000310 rehydration solution Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- YFESOSRPNPYODN-RSMWSHJLSA-N (2s,3s,4s,5r,6r)-6-[[(4s,6ar,6bs,8r,8ar,9r,10r,14br)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(z)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2s,3r,4s, Chemical compound O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(\C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(/C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YFESOSRPNPYODN-RSMWSHJLSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- GZSOSUNBTXMUFQ-NJGQXECBSA-N 5,7,3'-Trihydroxy-4'-methoxyflavone 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 GZSOSUNBTXMUFQ-NJGQXECBSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- AXNVHPCVMSNXNP-GKTCLTPXSA-N Aescin Natural products O=C(O[C@H]1[C@@H](OC(=O)C)[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@H]7[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O7)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C AXNVHPCVMSNXNP-GKTCLTPXSA-N 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- AFHJQYHRLPMKHU-XXWVOBANSA-N Aloin Natural products O=C1c2c(O)cc(CO)cc2[C@H]([C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)c2c1c(O)ccc2 AFHJQYHRLPMKHU-XXWVOBANSA-N 0.000 description 1
- 244000208874 Althaea officinalis Species 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000007497 Celosia trigyna Nutrition 0.000 description 1
- 244000257260 Celosia trigyna Species 0.000 description 1
- 241001233914 Chelidonium majus Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000012432 Collagen Type V Human genes 0.000 description 1
- 108010022514 Collagen Type V Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- 241000208698 Drosera Species 0.000 description 1
- 240000004530 Echinacea purpurea Species 0.000 description 1
- 240000002943 Elettaria cardamomum Species 0.000 description 1
- 241001632410 Eleutherococcus senticosus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- 241000169598 Galphimia Species 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 240000008669 Hedera helix Species 0.000 description 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 description 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 241001456088 Hesperocnide Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 241001126925 Lobata Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- MVLRKBFSYZGEQI-OHNFFSBGSA-N P(=O)(O)(O)O.O=C1C(O)=C(O)[C@H](O1)[C@@H](O)CO.C(CCCCCCCCCCCCCCCCC)(=O)O Chemical compound P(=O)(O)(O)O.O=C1C(O)=C(O)[C@H](O1)[C@@H](O)CO.C(CCCCCCCCCCCCCCCCC)(=O)O MVLRKBFSYZGEQI-OHNFFSBGSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 235000016787 Piper methysticum Nutrition 0.000 description 1
- 240000005546 Piper methysticum Species 0.000 description 1
- 235000010503 Plantago lanceolata Nutrition 0.000 description 1
- 244000239204 Plantago lanceolata Species 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 235000016311 Primula vulgaris Nutrition 0.000 description 1
- 244000028344 Primula vulgaris Species 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 244000061121 Rauvolfia serpentina Species 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 244000152640 Rhipsalis cassutha Species 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- QMQIQBOGXYYATH-IDABPMKMSA-N Ruscogenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)[C@H](O)C[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 QMQIQBOGXYYATH-IDABPMKMSA-N 0.000 description 1
- BSUPFYRQXCQGLJ-UHFFFAOYSA-N Ruscogenin Natural products CC1CCC2(OC1)OC3C(O)C4C5CC=C6CC(O)CC(O)C6(C)C5CCC4(C)C3C2C BSUPFYRQXCQGLJ-UHFFFAOYSA-N 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 229910021612 Silver iodide Inorganic materials 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000003591 Tagetes lucida Nutrition 0.000 description 1
- 240000002670 Tagetes lucida Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- BDIAUFOIMFAIPU-KVJIRVJXSA-N Valtratum Chemical compound C([C@]12[C@@H]3C(C(=CO[C@H]3OC(=O)CC(C)C)COC(C)=O)=C[C@@H]1OC(=O)CC(C)C)O2 BDIAUFOIMFAIPU-KVJIRVJXSA-N 0.000 description 1
- WKACQPMBGWZDMR-UHFFFAOYSA-N Vincamin Natural products CC=C1/CN2CCC34CC2C1C(=C3Nc5ccccc45)C=O WKACQPMBGWZDMR-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 235000014104 aloe vera supplement Nutrition 0.000 description 1
- CPUHNROBVJNNPW-UHFFFAOYSA-N aloin A Natural products OC1C(O)C(O)C(CO)OC1OC1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 CPUHNROBVJNNPW-UHFFFAOYSA-N 0.000 description 1
- AFHJQYHRLPMKHU-WEZNYRQKSA-N aloin B Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@H]1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-WEZNYRQKSA-N 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 150000004716 alpha keto acids Chemical class 0.000 description 1
- UNMLVGNWZDHBRA-UFAVQCRNSA-N alpha-L-Fucp-(1->3)-[alpha-D-Manp-(1->6)-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)]-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)O3)O[C@H]3[C@@H]([C@@H](O)[C@H](O)CO3)O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O UNMLVGNWZDHBRA-UFAVQCRNSA-N 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000012164 animal wax Substances 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000010477 apricot oil Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940067599 ascorbyl glucoside Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 150000004718 beta keto acids Chemical class 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000005300 cardamomo Nutrition 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 229920006319 cationized starch Polymers 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 229940112478 crataegus extract Drugs 0.000 description 1
- 239000010108 crataegus extract Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- ADYPXRFPBQGGAH-WVVAGBSPSA-N dihydroergotoxine Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-WVVAGBSPSA-N 0.000 description 1
- 229940120500 dihydroergotoxine Drugs 0.000 description 1
- GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 description 1
- 229960004352 diosmin Drugs 0.000 description 1
- IGBKNLGEMMEWKD-UHFFFAOYSA-N diosmin Natural products COc1ccc(cc1)C2=C(O)C(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 IGBKNLGEMMEWKD-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- QMQIQBOGXYYATH-UHFFFAOYSA-N epiruscogenin Natural products CC1C(C2(CCC3C4(C)C(O)CC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 QMQIQBOGXYYATH-UHFFFAOYSA-N 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000010647 garlic oil Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- AFHJQYHRLPMKHU-UHFFFAOYSA-N isobarbaloin Natural products OC1C(O)C(O)C(CO)OC1C1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002559 kavalactones Chemical class 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 235000020094 liqueur Nutrition 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 235000001035 marshmallow Nutrition 0.000 description 1
- 210000003784 masticatory muscle Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000012184 mineral wax Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000010665 pine oil Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 229940109990 ruscogenin Drugs 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- 229940045105 silver iodide Drugs 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 235000013706 tagetes lucida Nutrition 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- 229940068146 valepotriate Drugs 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A45—HAND OR TRAVELLING ARTICLES
- A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
- A45D44/00—Other cosmetic or toiletry articles, e.g. for hairdressers' rooms
- A45D44/002—Masks for cosmetic treatment of the face
Definitions
- the present invention relates to a flexible mask face mask and a kit-of-parts containing this face mask.
- Another object of the present invention is a method for producing the face mask according to the invention.
- the present invention relates to the use of the face mask or the kit-of-parts for the cosmetic treatment and / or for the therapeutic treatment of facial skin areas.
- Masks, sheets, matrices, overlays, pads, layers or similar flat forms play an important role here.
- Such embodiments are particularly suitable for the external and surface treatment and care of the skin as well as for the treatment of flat skin injuries or wounds.
- special, sometimes very specific material and functional requirements are to be imposed on such compositions, in particular on their chemical composition and their physical or biological-chemical action and mode of operation.
- the complex biochemical interactions and modes of functioning with the organ "skin" have to be considered.
- the care and the preventive protection by a cosmetic treatment can in particular by the introduction and contribution of active, Nursing and / or care agents are achieved, but also by supporting or improving the physical and mechanical protective and / or barrier properties, such as elasticity, smoothness, roughness, dryness or biochemical balance of the skin.
- the support, protection, regulation and improvement of the moisture and fat content, in particular the so-called "Natural Moisturizing Factor” (NMF) and the barrier function of the skin is an important treatment element.
- a treatment of particular importance is one that has a soothing, healing or restorative effect.
- Such therapeutic treatment may also be by delivery of certain positive-acting active ingredients, curatives or active ingredients or by suitable supporting physical or biochemical methods that support and favorably influence self-healing.
- the nature and extent of such a therapeutic treatment are dependent in particular on the type of injury or dysfunction and specifically tailored to the affected skin layers.
- solid, dry or premoistened, absorbent or hydratable preparation forms in particular in the form of flat masks, sheets, pads or pads, is in principle particularly suitable and already widespread for both areas, the nourishing cosmetic and the therapeutic area of the skin treatment ,
- particularly those preparations are of interest, which in addition to the active ingredient application also have a skin-hydrating and optionally cooling effect in itself. This is equally relevant for cosmetic as well as therapeutic skin treatment.
- the geometric configurations of the pads are of great importance and must be adapted to the respective body shapes to be treated in order to allow an efficient treatment of the skin.
- the present invention now relates to the specific technical field of face masks, and more particularly to specific geometric designs of face masks.
- a face mask in the sense of the present invention is understood to mean a mask which can be applied to at least a partial area of the face, whereby both the face mask itself, that is to say the face mask, are used by the present invention. in a form not applied to a face, as well as the facial mask already applied to a face is understood.
- a face mask is also understood to mean a mask for treating the human neck. In the context of the present invention, therefore, the neck is defined as belonging to the face.
- a face mask is also generally understood to mean a special care product which is moistened with warm or cold liquids and can be applied to the skin, in particular to the facial skin, and removed again after a certain exposure time. This is intended to support and supplement general skin care.
- a face mask which is integrally formed and openings corresponding to the mouth, nose and eyes of the user has.
- the face mask according to EP 0 063 875 A1 is designed to cover the entire facial area with the one-piece mask.
- US 5,656,279 is a face mask known, which is integrally formed. Special geometrical embodiments of the face mask are in the US 5,656,279 not described.
- US 2003/0190339 A1 is a face mask is known, which has in the head area, slightly left and right offset to the line connecting the forehead, nose and chin, wrinkles. This fold structure is used according to the example part of US 2003/0190339 A1 to adjust the size of the face mask to the face to be covered
- WO01 / 76550 is known a face mask, which consists of several separable subcomponents.
- a disadvantage of these known from the prior art face masks is that they do not allow a satisfactory flexible adaptation to different face shapes and it often comes to the application to a face to wrinkles of the mask or these must be cut before or during the application.
- the latter is particularly disadvantageous for hygienic and safety reasons, since the use of suitable cutting tools such as scissors or knives increases the potential for contamination with microorganisms introduced thereby or the risk of injury associated with their use.
- the face masks known in the prior art are not designed so that single facial areas can be treated completely in one piece with a single continuous mask or a single continuous portion of a mask. Also, a specific different treatment of individual parts of the face is not feasible with the face masks of the prior art.
- the present invention now has the object to solve the disadvantages described above and goes to solve these problems from a face mask (1) made of a flexible carrier material suitable for receiving liquids.
- the face mask according to the invention is in the FIGS. 1 to 3 , which will be referred to in the following, shown in detail.
- the face mask is modularly constructed from at least three different regions, namely the front segment (2), the cheek segment (3) and the neck segment (4).
- the individual regions are interconnected by perforations (5, 6) , so that it is possible to separate the individual segments (2, 3, 4) from each other and to use separately.
- the modular design of the face mask (1) allows an optimal adaptation of the face mask (1) to different types of face, such as facial skin. As Caucasian, Eurasian or Asian face types, or to the different face shapes, such as round, oval, heart-shaped, square or square face shapes, done as a displacement of the individual segments (2, 3, 4) after their separation is possible.
- the severing of the perforations (5, 6) and thus a disassembly of the face mask according to the invention in the corresponding segments can be done by simple tearing, eg manually.
- the segments (2, 3, 4) along the perforations (5, 6) can also be separated with the aid of suitable aids, such as a pair of scissors or a knife.
- the inventively provided modular construction of the face mask (1) of the end segment (2), cheek segment (3) and neck segment (4) allows a different loading of the segments with active ingredients and / or auxiliaries. This is important insofar as the facial skin is known to be in different zones, e.g. the so-called T-zone, U-zone, etc. can be divided, the different zones having a different skin structure or sensitivity with correspondingly different treatment, care or protection requirements.
- the individual segments (2, 3, 4) of the face mask (1) according to the invention are further designed such that with each segment an integral treatment of the corresponding facial parts is possible.
- the neck of a human can be completely treated on the front side with the integrally formed neck segment (4).
- the use of different segments is avoided in the respective parts of the face, which on the one hand facilitates the application of the face mask (1) according to the invention and on the other hand increases the wearing comfort.
- the cheek segment (3) of the face mask (1) according to the invention is designed so that the cheek segment (2) along the perforation (5) has an arcuate contour which extends at the edge in the direction of the end part (2).
- the masticatory muscle lies symmetrically in both jaws and has its attachment point on the outside of the cheekbone and runs to the outer jaw angle.
- the face mask (1) according to the invention is further characterized in particular in that the face mask (1) arranged between the frontal segment (2) and the cheek segment (3) above the cheek segment (3) has two regions (7, 8) which correspond to the two Eye areas correspond to a human face. These regions (7, 8) are preferably connected to one another by perforations (5a, 5b) with the front segment (2) and the cheek segment (3) such that the regions (7, 8) are removed altogether from the face mask (1) according to the invention can.
- the two areas (7, 8) are designed so that they can be used after the separation from the face mask (1) for the treatment of other skin areas of the human face.
- the areas below the eyes of a face are particularly suitable. The efficient use of excess mask material can significantly reduce the need to make appropriate face masks.
- the detachably formed regions (7, 8) can be used both simultaneously with the other segments (2, 3, 4) of the face mask (1) according to the invention or else separately, for example at a later time.
- the areas (7, 8) are generally of a substantially oval shape, the substantially oval regions (7, 8) extending downwardly to the cheek segment (3) and tapering to the nasal bone of a human face Nasal bone of a human face tapering extensions (22, 23) have.
- the corresponding mask parts be used very close to the human eye so that the formation of eye wrinkles is effectively treated (cf. FIG. 3 ).
- the segments (7, 8) have a contour adapted to this requirement.
- the face mask (1) according to the invention between the end segment (2) and the cheek segment (3) below the end segment (2) arranged on a region (9), which corresponds to the nasal wing region of a human face.
- This region (9) is connected to one another by perforations (5c, 5d) with the front segment (2) and the cheek segment (3) so that the region (9) can be removed from the face mask (1).
- the area (9) is preferably designed such that it can be used after being separated from the face mask (1) for a further skin zone of the human face, in particular the glabella area of the human face (cf. FIG. 3 ).
- the distance a between two horizontal lines (29, 30) which is at the level of the lowest point A of the area (9) and the uppermost points B and B 'of the arch at least 2.5 cm, preferably at least 3, 0 cm, more preferably at least 3.5 cm, more preferably at least 4.0 cm, more preferably at least 4.5 cm, particularly preferably at least 5.0 cm,
- the face mask (1) according to the invention can be used by as many people as possible with different facial types, it is preferred if the end segment (2) and the cheek segment (3) are designed so that they can be displaced along the vertical course of the human face when applying both segments on the human face, wherein areas of the end segment (2) and of the cheek segment (3) can overlap. For this purpose, a previous separation of the individual segments (2, 3, 4) along the perforations (5, 6) is required.
- the front part (2) of the face mask (1) according to the invention has a substantially T-shaped structure, which extends in an arcuate manner downwards in the edge region in the direction of the cheek segment (3).
- the end segment (2) has a region (11) which corresponds to the nasal wing region of a human face, the region (11) widening in the direction of the cheek segment (3).
- this area is formed as a perforation (20, 21)
- a special stability of the unused face mask is achieved, and an undesired breakup of the individual segments, in particular of the segments (2, 3), can be prevented.
- the face mask (1) according to the invention that in the left and / or right edge region (12, 13) of the face mask (1) adjacent to the regions (7, 8) Recesses (14, 15) are present or regions (14, 15) which are connected to the front segment (2) and the cheek segment (3) by edge cuts and / or perforations so that a separation of the regions (14, 15) Forming recesses (14, 15) from the face mask (1) according to the invention is possible.
- the corresponding areas (14, 15) can thus either be completely removed or the face mask (1) has a perforation with which corresponding recesses (14, 15) can be easily formed.
- the areas (14, 15) are excluded from the face mask (1) according to the invention, it is easy for the user to separate out the areas (7, 8) which correspond to the eye areas of the human face and which are generally used separately.
- the recesses (14, 15) or the areas (14, 15) are substantially triangular in shape, wherein it is even more preferable if the substantially triangular recesses (14, 15) or areas (1 4, 15) face outward and taper outwards into a point (16, 17).
- This also improves the stability of the unused face mask and disassembly of the face mask according to the invention into the individual segments is easily possible.
- the face mask (1) it is also possible for the face mask (1) to have a point (16, 17) of the recesses (14, 15) or of the areas (14, 15) pointing from the outer edge (18, 19) to the outwardly pointing tip (16, 17) ) reaching edge section (20, 21).
- the perforation (6) connecting the cheek segment (3) and the neck segment (4) is not continuous to the left and / or right outer edge (18, 19) of the face mask (FIG. 1), but in the left and / or right edge region (12, 13) of the face mask (1) ends and the further course is formed to the right and / or left outer edge of the face mask (1) in the form of one or more edge cuts.
- the lower edge of the cheek segment (3) formed by such edge cuts and / or the upper edge of the neck segment (4) can be opposite the other adjacent edge in an arcuate manner to the right and / or left outer edge (18, 19) of the face mask (1).
- the end segment (2) and the cheek segment (3) adjoin one another between the regions (7) and (9) and (8) and (9) ,
- the face mask according to the invention preferably has an opening (10) in the area of the mouth in the cheek segment (3).
- the oral section provided is not subject to any particular restriction and may have any suitable shape and size.
- the opening (10) is formed as a recess.
- the area which is provided as an opening (10) for the mouth area with a corresponding perforation (10a) with which a corresponding opening (10) can easily be formed by separating out the mask material.
- the face mask in the lower edge region (24) of the neck segment (4) substantially comprises one or more vertical perforations (25) or cuts (25) which allow the formation of incisions in the neck segment (4) , on.
- the vertical cuts (25) generally have a length of at least 0.5 cm, preferably at least 1.0 cm, more preferably at least 1.5 cm, more preferably at least 2.0 cm.
- the vertical cuts (25) generally have a length of at most 3.0 cm, preferably at most 2.5 cm, more preferably at most 2.0 cm.
- the face mask (1) according to the invention preferably has, starting from the perforation (6), one or more incisions (26) or perforations (26) which extend into the cheek segment (3) and allow the formation of incisions in the cheek segment (3). on.
- the vertical cuts (26) generally have a length of at least 0.5 cm, preferably at least 1.0 cm, more preferably at least 1.5 cm, more preferably at least 2.0 cm.
- the vertical cuts (26) generally have a length of at most 3.0 cm, preferably at most 2.5 cm, more preferably at most 2.0 cm.
- the face mask (1) according to the invention preferably has, starting from the perforation (6), one or more incisions (27) or perforations (27) which extend into the neck segment (4) and allow the formation of incisions in the neck segment (4). on.
- the vertical cuts (27) generally have a length of at least 0.5 cm, preferably at least 1.0 cm, more preferably at least 1.5 cm, more preferably at least 2.0 cm.
- the vertical cuts (27) generally have a length of at most 3.0 cm, preferably at most 2.5 cm, more preferably at most 2.0 cm.
- the face mask (1) according to the invention in the end segment (2) preferably starting from the edge region of the upper part of the area provided for the cover of the nose (11), which adjoins the removable regions (7, 8), in the front segment (2 ) in substantially horizontal incisions (28) or perforations (28), which allow the formation of substantially horizontal incisions in the frontal segment (2), on.
- the horizontal incisions (28) generally have a length of at least 0.2 cm, preferably at least 0.4 cm, more preferably at least 0.6 cm, more preferably at least 0.8 cm.
- the horizontal cuts (28) generally have a length of at most 1.2 cm, preferably at most 1.0 cm, more preferably at most 0.8 cm.
- incisions in each case in the same lengths or in different lengths, for example in Abjokeit from their placement on the mask segments.
- incisions are made shorter than rather incisions placed at the edge.
- the face mask is formed as in the illustration 1 shown.
- the reference numerals of FIG. 1 refer to the above explanations.
- FIG. 2 shows the distance a between two lines passing through the imaginary points A, B and B 'of the face mask according to FIG FIG. 1 to run.
- FIG. 3 shows another use of the removable segments (7, 8, 9).
- the blank of the face mask according to the invention is designed so that with a minimum blending a total of six different segments for facial and neck treatment can be made from only one DIN A4 sheet. This ensures maximum utilization of an A4 sheet.
- the face mask according to the invention comprises a carrier material.
- this carrier material must be suitable for receiving liquids, since the application of the face masks according to the invention usually takes place in a moistened or pre-moistened form or a moistening is carried out in the course of the application.
- the support material must be selected so that the masks available therefrom have sufficient stability to be converted by cutting and perforation in the geometric shape of the invention can.
- the face masks according to the invention must have sufficient mechanical stability in order also during use or during the course of the application, in particular during separation the perforated segments, as well as when applying and modeling the individual segments on the body region to be treated, both in the dry and in the moistened state to remain dimensionally stable and in particular not to tear.
- the carrier material is selected from the group consisting of proteins, such as. As collagen, gelatin, elastin, keratin, fibroin, albumin, with collagen, if appropriate, is also particularly preferred in admixture with other fibrillar proteins.
- proteins such as collagen, gelatin, elastin, keratin, fibroin, albumin, with collagen, if appropriate, is also particularly preferred in admixture with other fibrillar proteins.
- collagen-based carrier materials it is preferable to select those materials known in the art. For example, on the DE 40 28 622 or on the DE 103 50 654 directed.
- the preferred collagen carrier materials are distinguished, in particular, by outstanding hydration properties and good absorbency, as well as by their anti-irritative and skin-soothing properties. Due to the structural similarity to human skin and tissue, collagen species found in the skin and tissues are most preferably used. These include, in particular, collagen type I, III and V. In this way, a particularly good compatibility and biocompatibility of the carrier material with the skin is achieved.
- the carrier materials selected in this way are biodegradable in the body and can therefore be naturally degraded.
- the collagenous carrier material is preferably derived from collagen sources from cattle, horses and pigs. Bovine collagen is very particularly preferred.
- the carrier material may, for. B. soluble or insoluble animal or vegetable collagen such. B. fish collagen or mixtures thereof.
- the collagen can be prepared by conventional methods, such as in DE 103 50 654 described by the Applicant, are obtained from the usual sources, such as skins or tendons. Mixtures of, for example, collagen and gelatin, or more preferably collagen and elastin, may also be used.
- collagen materials be used, which were subjected to a crosslinking reaction. In this case, thermal crosslinking, the so-called dehydrothermal crosslinking, is preferred.
- the crosslinking with chemical crosslinkers is possible.
- aldehydes such as glutaraldehyde
- Carbodiimides such as EDC
- isocyanates Epoxides or imidazoles, wherein the epoxide from the group of chemical crosslinkers is particularly preferred.
- the carrier material of the face mask may also be a vegetable carrier material.
- one of the group of natural structure-forming polymers is preferably selected, preferably from the group of polysaccharides or glucosaminoglycans.
- the natural polymers are selected from the polysaccharides.
- Polysaccharides include, for example, homoglycans or heteroglycans, such as alginates, especially sodium alginate, carrageenan (optionally also referred to herein by the common English name "carragenan”), pectins, pullulan, tragacanth, guar gum, locust bean gum, agar-agar, gum Arabic, xanthan, pullulan, natural and modified starches, dextrans, dextrin, maltodextrins, chitosan, glucans, such as ⁇ -1,3-glucan, ⁇ -1,4-glucan, such as cellulose, mucopolysaccharides, such as hyaluronic acid, etc., or Mixtures thereof.
- one of the above-mentioned different polymer, for. B. to select those from the group of synthetic and / or semi-synthetic and / or modified natural polymers.
- Such synthetic, semi-synthetic or modified natural polymers include, for example, cellulose ethers, polyvinyl alcohol, polyvinylpyrrolidone, synthetic cellulose derivatives such as methylcellulose, carboxycellulose, carboxymethylcellulose, sodium carboxymethylcellulose, cellulose esters, cellulose ethers such as hydroxypropylcellulose, polyacrylic acid, Polymethacrylic acid, poly (methyl methacrylate) (PMMA), polymethacrylate (PMA), polyethylene glycols, cationized celluloses or cationized starches, etc.
- the carrier materials can be laminated or the carrier materials can be present in the form of multilayer, interconnected layers.
- laminates conventional materials known in the art, e.g. Fibers, nonwovens, nets, films or foils of suitable materials, e.g. Rayon, cellulose, polyethylene (PE) or polyurethane (PU) or other synthetic or semi-synthetic polymers / copolymers prepared by conventional methods, e.g. by gluing, hot lamination, crosslinking, etc. with the carrier materials in the context of the present invention can be firmly connected.
- Such a lamination is particularly suitable for increasing the mechanical stability of the carrier materials for producing the face masks according to the invention, as well as for improving their handleability during application, especially in the moistened state.
- the polymeric support materials according to the invention can by conventional methods, such as in the DE 103 50 654 , of the WO 04/104076 , of the WO 05/113656 or the WO 08/020066 described by the applicant.
- the polymers of the face mask according to the invention have good biocompatibility and are in particular compatible with the skin and mucous membranes and have no toxicological effects either when used on intact skin or when introduced into one of the lower skin layers, for example in wounds which have an injury or destruction of the natural skin structure Potential. Also, the polymers to be used according to the invention do not cause any irritation effects or other incompatibility reactions when applied. They are pharmacologically completely harmless and therefore optimal suitable as polymer material for the cosmetic and pharmaceutical dermal uses according to the invention.
- the face mask according to the invention may additionally comprise at least one active substance.
- At least one active substance is contained in such face masks according to the invention.
- Active ingredients include, in particular, cosmetic or therapeutic or pharmaceutical agents suitable for external use. Accordingly, such freeze-dried compositions of the invention are preferably cosmetic or therapeutic agents.
- Cosmetic agents or agents produced using cosmetic agents in the context of the invention are essentially agents within the meaning of the Food, Commodities and Feed Code (LFGB), ie, substances or preparations of substances which are intended to be externally to humans for cleaning , Care, or to influence appearance or body odor, or to mediate the expression of olfaction, unless they are primarily intended to relieve or eliminate disease, suffering, bodily injury or pathological condition.
- the cosmetic moldings used according to the invention are, for example, bath preparations, skin cleansing and cleansing compositions, skin care products, in particular facial skin care products, eye cosmetics, lip care products, nail care products, foot care products, hair care products, in particular shampoos, hair conditioners, hair conditioners, sunscreen agents, skin tanning agents. and brightening agents, depigmenting agents, deodorants, antiperspirants, hair removing agents, insect repellents, etc. or such agents in combination.
- cosmetically optionally also, for example, dermatological, therapeutically active compounds include: anti-acne agents, antimicrobials, antiperspirants, astringents, deodorizing agents, depilatory agents, conditioning agents for the Skin, skin smoothing agents, skin hydration enhancers such as: As glycerol or urea, sunscreens, keratolytics, radical scavengers for free radicals, anti-seborrhea, anti-dandruff agents, antiseptic agents, agents for the treatment of signs of aging and / or modulating the differentiation and / or proliferation and / or pigmentation of the skin, vitamins such as vitamin C (ascorbic acid) and its derivatives such as glycosides such as ascorbyl glucoside or esters of ascorbic acid such as sodium or magnesium ascorbyl phosphate or ascorbyl palmitate and stearate L-ascorbic acid phosphate ester, alkali metal salts such as sodium and potassium salts of L
- Excipients with irritating side effects such as alpha hydroxy acids, beta hydroxy acids, alpha keto acids, beta keto acids, retinoids (retinol, retinal, retinoic acid) anthralines (dioxyanthranol), anthranoids, peroxides (especially benzoyl peroxide), minoxidil, lithium salts, antimetabolites , Vitamin D and its derivatives; Catechins, flavonoids, ceramides, polyunsaturated fatty acids, essential fatty acids (eg gamma-linolenic acid), enzymes, coenzymes, enzyme inhibitors, hydrating agents, skin soothing agents, detergents or foam-forming agents, and inorganic or synthetic matting fillers, or decorative materials such as pigments or dyes and particles for foundations, make-up formulations, and other agents for cosmetic embellishment and color design of the eyes, lips, face etc. as well as abrasive agents.
- retinoids retinol, retinal, retinoi
- plant extracts or extracted extracts or individual substances can be mentioned.
- the plant extract is typically selected from the group consisting of solid plant extracts, liquid plant extracts, hydrophilic plant extracts, lipophilic plant extracts, individual plant ingredients; and mixtures thereof, such as flavonoids and their aglycans: rutin, quercetin, diosmin, hyperoside, (neo) hesperidin, hesperitin, ginkgo biloba (eg ginkoflavone glycosides), Crataegus extract (eg oligomeric procyanidins), buckwheat (eg rutin), Sophora japonica ( eg rutin), birch leaves (eg Quercetinglykoside, hyperoside and rutin), elderflower (eg rutin), lime blossom (eg.
- Echinacea purpurea for example, alcoholic extracts, fresh vegetable juice, pressed juice), Eleutherococcus senticosus; alkaloids; Caffeine, tein, theobromine, rauwolfia (e.g., prjmalin), evergreen (e.g., vincamin); other herbal medicines: aloe, horse chestnut (eg Aescin), garlic (eg garlic oil), pineapple (eg bromelaine), ginseng (eg ginseno-side), milk thistle fruits (eg silymarin standardized extract), butcher's root (eg ruscogenin), valerian (eg valepotriate , Tct.
- Kava-Kava eg Kavalactone
- hop flowers eg hop bitter substances
- Extr. Passi-florae eg ethanol extract
- anthraquinone-containing drug extracts eg aloin-containing aloe vera juice, pollen extract, algae extracts, liquorice root extracts, palm extract, galphimia (eg, tincture), mistletoe (eg, aqueous ethanol extract), phytosterols (eg, beta-sitosterol), wool flowers (eg, aqueous-alcohol extract), drosera ( eg liqueur wine extract), sea buckthorn fruits (eg juice or sea buckthorn oil derived therefrom), marshmallow root, primrose root extract, fresh plant extracts from mallow, comfrey, ivy, horsetail, yarrow, ribwort (eg pressed juice), stinging nettle, celandine, parsley; Plant extracts from No
- the therapeutic face masks to those containing at least one pharmaceutical or therapeutic, especially dermatological active ingredient and which are intended under the Medicines Act, inter alia, to cure, alleviate or prevent diseases, disorders, body damage or pathological complaints .
- those agents or active substances are particularly suitable for external or transdermal application, in particular in the field of wound treatment and healing as well as in the treatment of burn injuries, in particular for the initial supply of burns, preferably already as a first aid measure at the accident site , are determined.
- those active ingredients or active ingredient compositions are also preferred which reduce posttraumatic tissue damage, the so-called afterburning and thus prevent a worsening situation occurring after the actual damage event by supplying moisture to the fresh burn wound, reducing overheating, and cellular care, especially in the marginal area the wound is improved and an oxidative cell damage is prevented while calming the surrounding skin, reducing the sensation of pain and improving wound healing.
- Active substances for such a dermal or transdermal application are in particular skin-active but also transdermal active substances. They include, for example: agents for the treatment of burn injuries, especially in primary care, such as known from the US 4870002 , of the JP 10-017480 or the US 5958420 , Agents for the treatment of skin diseases, externally applicable analgesics, e.g. Dextropropoxyphene, pentazocine, pethidine, buprenorphine; Anti-inflammatory drugs / anti-inflammatory drugs (NSAIDs), eg.
- benzbromarone allopurinol
- Dermatological preparations antihistamines, antibiotics, including antibacterial agents, such as colloidal silver and silver salts, antifungals, Peptidarznei für, antiviral agents, anti-inflammatory agents, antipruritic agents, anesthetizing agents, eg. Benzocaine, corticoids, acne, antiparasitic agents; externally applicable hormones; Veins therapeutics; Immunosuppresives etc. all for dermal or transdermal use.
- antibacterial agents such as colloidal silver and silver salts, antifungals, Peptidarzneistoffe, antiviral agents, anti-inflammatory agents, antipruritic agents, anesthetizing agents, eg. Benzocaine, corticoids, acne, antiparasitic agents; externally applicable hormones; Veins therapeutics; Immunosuppresives etc. all for dermal or transdermal use.
- Preferred therapeutic agents for dermal and transdermal use are agents for the treatment of burn injuries, especially for the acute or primary care of burn wounds and, in this context, in particular, agents with moisturizing, cooling, anesthetizing, anti-inflammatory action or mixtures thereof;
- Agents for the treatment of skin diseases such as atopic dermatitis, atopic dermatitis, etc., and anti-herpes agents, and in particular those used in the field of wound treatment, in particular for the treatment of chronic wounds, bedsores, leg ulcers, etc., such as analgesics, eg Immunosuppressants, hormones, anesthetizing agents, antiparasitic, fungicidal or antifungal and antibacterial agents such as in particular silver-containing agents such.
- silver nitrate silver chloride, silver iodide or other known from the prior art silver-containing wound care agents, agents to support and regulate the wound environment such as in particular electrolytes, silica, minerals and trace elements such.
- agents to support and regulate the wound environment such as in particular electrolytes, silica, minerals and trace elements such.
- bronchial therapeutics such as antiasthmatics, antitussives, mucolytics, etc.
- antidiabetics such as glibenclamide, hormones, steroid hormones such as dexamethasone, cardiac glycosides such as digitoxin, cardiovascular therapeutics such.
- Beta-blockers, antiarrhythmics, antihypertensives, calcium antagonists etc psychotropic and antidepressants such as tricyclic antidepressants (NSMRI), serotonin reuptake inhibitors (SSRIs), norepinephrine reuptake inhibitors (NRIs), serotonin norepinephrine Recovery Inhibitors (SNRI), monoamine oxidase inhibitors (MAOIs) etc., neuroleptics, anticonvulsants or antiepileptics, hypnotics, sedatives, anesthetics, gastric and intestinal therapies, lipid lowering agents, analgesics such.
- NSMRI tricyclic antidepressants
- SSRIs serotonin reuptake inhibitors
- NRIs norepinephrine reuptake inhibitors
- SNRI serotonin norepinephrine Recovery Inhibitors
- MAOIs monoamine oxidase inhibitors
- hydrocolloids especially those based on natural polymers such as polysaccharides, may also have certain therapeutic effects.
- the preferred hydrocolloid (sodium) alginate used is antiviral to some extent, and hyaluronic acid is said to have some re-epithelializing activity and as an antioxidant and moisturizer in skin care, but they are not active agents in the meaning of the invention.
- the face mask according to the invention may further comprise at least one adjuvant.
- Adjuvants include pH adjusting agents such as buffering agents, inorganic and organic acids or bases; Fatty substances such as mineral oils such as paraffin oils or vaseline oils, silicone oils, vegetable oils such as coconut oil, sweet almond oil, apricot oil, corn oil, jojoba oil, olive oil, avocado oil, sesame oil, palm oil, eucalyptus oil, rosemary oil, lavender oil, pine oil, thyme oil, mint oil, cardamom oil, orange blossom oil, soybean oil, Bran oil, rice oil, rapeseed oil and castor oil, wheat germ oil and vitamin E isolated therefrom, evening primrose oil, plant lecithins (eg soya lecithin), sphingolipids / ceramides isolated from plants, animal oils or fats such as tallow, lanolin, butter oil, neutral oil, squalane, fatty acid esters, esters of Fatty alcohols such as triglycerides; and waxes having a melting point corresponding to skin temperature (animal
- oils are preferred.
- cosmetic oils as listed above, in particular triglycerides, more preferably caprylic / caproic acid triglycerides, squalane or jojoba oil are preferred.
- the face masks according to the invention are obtainable by cutting, pre-perforating and / or perforating, punching and / or cutting of layered or sheet-shaped carrier materials as described above, in particular of those which are in the form of freeze-dried materials, into the desired geometric shape according to FIG above-described inventive face mask and optionally provided the face mask or the individual segments with an embossing and / or a colored print.
- the wet tensile strength of the inventively preferred support materials is preferably at least 50 mN / mm layer thickness, more preferably 100 mN / mm, even more preferably 200 mN / mm.
- optical density refers to the quantitative unit of optical density, measured as a decadic logarithm of the ratio of transmitted light intensity to irradiated light intensity, determined using a Heiland SW Densitometer TD 03 on freeze-dried face masks with a layer thickness of 1 mm.
- the compositions of the present invention preferably have an optical density of ⁇ 0.02, more preferably ⁇ 0.03, more preferably ⁇ 0.05, per mm of layer thickness.
- a high optical density is advantageous, for example, for those face masks which are colored with colored printings, e.g. in the form of aesthetic form and color designs, lettering, logos or explanations should be provided.
- Blanks can be individually packaged, which is particularly preferred in therapeutic or pharmaceutical but also in professional cosmetic application. Blanks for cosmetic use can also be present in a plurality of side by side or one above the other in contact in a suitable container or a suitable packaging.
- the face masks according to the invention are used for external cosmetic as well as external and transdermal pharmaceutical application.
- the external application is carried out in particular in the cosmetic application so that the various segments are separated from each other at the designated perforations before use and dry applied to the body parts to be treated and there with water or an aqueous solution containing one or more active ingredients and / or one or more adjuvants (a so-called activator solution), moistened and rehydrated.
- activator solution a so-called activator solution
- Another object of the present invention is a care or treatment set containing at least one face mask as described above.
- the present invention relates to the use of a face mask (1) according to the invention for the cosmetic treatment of facial and neck skin areas.
- the present invention also relates to a combination comprising at least one of the face masks according to the invention or their blanks and at least one aqueous solution which contains one or more active ingredients and / or at least one or more auxiliaries (a so-called activator solution) in an associated, spatial arrangement (Application package, set, kit-of-parts, etc.).
- aqueous solution which contains one or more active ingredients and / or at least one or more auxiliaries (a so-called activator solution) in an associated, spatial arrangement (Application package, set, kit-of-parts, etc.).
- the active substance solution may be, for example, solutions of readily volatile active ingredients and / or adjuvants which, owing to the production process, for example, should not be introduced into a freeze-dried face mask, for example certain proportions of essential oils, perfumes, etc It is also possible to include those active ingredients and / or adjuvants which have a moisturizing effect, especially in the case of the external achieve moisturizing effect, which is particularly desirable and preferred for external application to the skin, and which can not be incorporated or only in small amounts in the present invention preferred freeze-dried compositions due to this moistening effect or due to hygroscopic tendencies, since the stability possibly contained moisture-labile substances can no longer be maintained.
- one or more of the aforementioned active ingredients and / or auxiliaries may be present in the activator solutions.
- such drug solutions may be included in the kit-of-parts embodiments that are suitable for the rehydration and cooling of burn wounds, especially in the acute and primary care of burn injuries.
- rehydration solutions are known from the prior art. These are u.a. also to physiological solutions or electrolyte-containing solutions, which may optionally contain other suitable active ingredients, as stated above.
- the preferred embodiments are preferably aqueous activator or rehydration solutions, for which reason the combination in a kit-of-parts arrangement with a face mask of a hydrophilic, open-pored, absorbent carrier material according to the invention is then particularly preferred.
- An open-pore sponge-like foam structure as it is present in particular in freeze-dried carrier materials, is particularly preferred since the carrier material of the face mask has a high absorbency and if suitable polymers are selected, for example from the group comprising collagen, alginates, hyaluronic acid and / or polyacrylates (carbomers). , ideally also has a high fluid intake and holding capacity.
- Another important effect of this preferred application is the ability to dissipate heat simply and over a large area by creating a cooling effect through the evaporation of the liquid.
- Cooling is not only beneficial in the treatment of burn injuries, but also in damaged skin z. As in sunburns or sports injuries or to relieve painful and unpleasant skin inflammation or to relieve side effects of irritating cosmetic treatments such. As exfoliation, laser, Fraxel or Resurfacing oppositionen. In this case, it is particularly desirable to allow the cooling effect to be sustained over a relatively long period of time, which can be achieved, in particular, by the particularly preferred hydrophilic, open-pored, absorbent carrier materials described above.
- a hydrophobic material would not be able to absorb an aqueous drug solution.
- the use of a hydrophobic material in combination with a hydrophobic drug solution z. B. based on fats and oils is due to the completion of the wound (the so-called occlusion) with prevention of transmission and heat dissipation disadvantageous and therefore undesirable.
- kits-of-parts embodiments at least one of the face masks according to the invention or their blanks with more than one, mutually different solutions, which contains one or more active ingredients and / or at least one or more excipients in a belonging together , spatial arrangement (application package, set, kit-of-parts, etc.).
- the different activator solutions are provided for rehydration of the various face mask segments and their composition is specifically tailored to the corresponding body part to be treated. This is inasmuch as the facial skin is known to be divided into different zones, such as T-zone, U-zone, etc., wherein the different zones have a different skin structure or sensitivity with correspondingly different treatment, care or protection requirement.
- the area of the so-called T-zone which includes in particular the forehead and the nose, is usually a less sensitive and prone to skin blemishes and increased skin fat formation area, whereas, for example, the area of the cheeks is more prone to skin dryness.
- the area under the eyes is characterized by an extreme Dünnkorutmaschine and high sensitivity with increased wrinkling. Due to the immediate proximity to the extremely sensitive mucous membranes of the eye, the application of irritant or spreading active ingredients or auxiliaries is only conditionally or even impossible.
- the facial area has typical problem areas that require special treatment with active ingredients.
- kit-of-parts combinations of inventive face mask on the one hand and drug solution on the other hand can provide that the two components are removed separately from the kit-of-parts arrangement and are brought together outside for further use.
- a combination of the components within the kit-of-parts packaging, for example in chambers provided for this purpose, itself and the rehydrated composition is then supplied directly from this further cosmetic or pharmaceutical external or transdermal use. This can preferably be carried out directly by the end user.
Landscapes
- Cosmetics (AREA)
Claims (14)
- Masque facial (1) fait d'un matériau de support flexible capable d'absorber des liquides, où le masque facial comprend un segment du front (2), un segment des joues (3) et un segment de la gorge (4), oùa. les segments individuels (2) à (4) sont reliés par des perforations (5, 6) de manière à ce que les segments (2) à (4) puissent être séparés les uns des autres ;b. les segments individuels (2) à (4) sont chacun formés de manière à ce qu'ils puissent intégralement recouvrir les zones du visage correspondantes d'un visage humain; caractérisé en ce quec. le segment des joues (3) présente un contour en forme d'arc le long de la perforation (5), qui se prolonge sur le bord dans la direction de la partie du front (2).
- Masque facial (1) selon la revendication 1, caractérisé en ce qued. le masque facial (1) présente deux zones (7, 8) entre le segment du front (2) et le segment des joues (3) au-dessus du segment des joues (3), qui correspondent aux deux zones des yeux d'un visage humain ;e. les zones (7, 8) sont reliées par les perforations (5a, 5b) avec le segment du front (2) et avec le segment des joues (3) de manière à ce que les zones (7, 8) puissent être séparées du masque facial (1) ; etf. les deux zones (7, 8) sont formées de manière à ce qu'après avoir été séparées du masque facial (1) elles puissent être utilisées pour d'autres zones de peau du visage humain, particulièrement dans la zone directement sous les yeux du visage humain.
- Masque facial (1) selon la revendication 2, caractérisé en ce que les zones (7, 8) ont une forme essentiellement ovale, où les zone essentiellement ovales (7, 8) présentent des extensions (22, 23) qui se prolongent vers le bas en direction du segment des joues (3) et se rétrécissent progressivement dans la direction de l'os du nez d'un visage humain.
- Masque facial (1) selon l'une quelconque des revendications 1 à 3, caractérisé en ce queg. le masque facial (1) présente entre le segment du front (2) et le segment des joues (3) sous le segment du front (2) une zone ajustée (9), qui correspond à la zone des côtés du nez d'un visage humain ;h. la zone (9) est reliée par les perforations (5c, 5d) avec le segment du front (2) et avec le segment des joues (3) de manière à ce que la zone (9) puisse être retirée du masque facial (1) ; eti. la zone (9) est formée de manière à ce qu'après être retirée du masque facial (1) elle puisse être utilisée pour une autre zone de peau du visage humain, particulièrement pour la zone de la glabelle du visage humain.
- Masque facial (1) selon l'une quelconque des revendications 1 à 4, caractérisé en ce que la distance a entre deux lignes horizontales (28, 29) situées à la hauteur du point A le plus bas de la zone (9) et des points B et B' les plus élevés de la perforation (5) entre la partie du front (2) et la partie des joues (3), est de au moins 2,5 cm, de préférence de au moins 3,0 cm, plus préférablement de au moins 3,5 cm, plus préférablement de au moins 4,0 cm, plus préférablement de au moins 4,5 cm, particulièrement préférablement de au moins 5,0 cm.
- Masque facial (1) selon l'une quelconque des revendications 1 à 5, caractérisé en ce que la partie du front (2) présente une structure essentiellement en forme de T, qui se prolonge sur le bord en forme d'un arc dans la direction du segment des joues (3).
- Masque facial (1) selon l'une quelconque des revendications 1 à 6, caractérisé en ce que le segment du front (2) présente une zone (11), qui correspond à la zone du nez d'un visage humain, où la zone (11) s'élargie dans la direction du segment des joues (3).
- Masque facial (1) selon l'une quelconque des revendications 1 à 7, caractérisé en ce que dans la zone du bord gauche et/ou dans la zone du bord droit (12, 13) du masque facial (1) au voisinage des régions (7, 8) il y a des évidements (14, 15) ou des zones perforées (14, 15) prévues pour la formation d'évidements.
- Masque facial (1) selon la revendication 8, caractérisé en ce que les évidements (14, 15) ou les zones perforées (14, 15) sont de forme essentiellement triangulaire et particulièrement préférablement pointent vers l'extérieur et se rétrécissent vers l'extérieur en une pointe (16, 17).
- Masque facial (1) selon l'une quelconque des revendications 1 à 9, caractérisé en ce que le segment des joues (3) présente un segment coupé (10), qui correspond à la zone de la bouche d'un visage humain.
- Masque facial (1) selon l'une quelconque des revendications 1 à 10, caractérisé en ce que le masque facial (1) présente une ou plusieurs coupures essentiellement verticales (25, 26, 27) ou perforations (25, 26, 27) qui permettent la formation de coupures, dans la zone inférieur du bord (24) du segment de la gorge (4) et/ou se prolongeant depuis la perforation (6) dans le segment des joues (3) et/ou se prolongeant dans le segment de la gorge (4).
- Combinaison sous forme de kit de pièces comprenant au moins un masque selon l'une quelconque des revendications 1 à 11 et au moins une solution aqueuse, qui comprend une ou plusieurs substances actives et/ou si applicable un ou plusieurs excipients.
- Utilisation d'un masque facial selon l'une quelconque des revendications 1 à 11 ou d'une combinaison sous forme de kit de pièces selon la revendication 12 pour le traitement cosmétique de zones de peau du visage.
- Masque facial selon l'une quelconque des revendications 1 à 11 ou une combinaison sous forme de kit de pièces selon la revendication 12 pour le traitement thérapeutique de zones de peau du visage, de préférence pour le traitement de brûlures, en particulier pour l'utilisation en tant que traitement intensif ou soins d'urgence en cas de brûlures.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10158628.7A EP2371237B1 (fr) | 2010-03-31 | 2010-03-31 | Masque facial |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10158628.7A EP2371237B1 (fr) | 2010-03-31 | 2010-03-31 | Masque facial |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2371237A1 EP2371237A1 (fr) | 2011-10-05 |
EP2371237B1 true EP2371237B1 (fr) | 2015-08-26 |
Family
ID=42736856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10158628.7A Active EP2371237B1 (fr) | 2010-03-31 | 2010-03-31 | Masque facial |
Country Status (1)
Country | Link |
---|---|
EP (1) | EP2371237B1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2743916C1 (ru) * | 2020-07-28 | 2021-03-01 | Владимир Николаевич Школьный | Маска косметическая сегментированная однократного применения |
DE202022106557U1 (de) | 2022-11-23 | 2022-12-02 | Elena Berkana | Netz-Gesichtsmaske |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10905646B2 (en) | 2014-10-31 | 2021-02-02 | Lubrizol Advanced Materials, Inc. | Thermoplastic polyurethane film for delivery of active agents to skin surfaces |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4870002A (en) | 1981-04-07 | 1989-09-26 | The United States Of America As Represented By The Secretary Of The Air Force | Method of prevention of oxidative injury to cells |
JPS57166514U (fr) | 1981-04-16 | 1982-10-20 | ||
DE4028622C2 (de) | 1990-09-08 | 1994-01-27 | Suwelack Nachf Dr Otto | Verfahren zum Herstellen von Kollagenschwämmen |
DE4328329C2 (de) | 1992-08-26 | 1998-02-12 | Suwelack Nachf Dr Otto | Gefriergetrocknete Biomatrix |
US5656279A (en) | 1994-02-23 | 1997-08-12 | Bio Med Sciences, Inc. | Semi-interpenetrating polymer network scar treatment sheeting, process of manufacture and useful articles thereof |
JPH1017480A (ja) | 1996-07-01 | 1998-01-20 | Osaka Ship Building Co Ltd | 皮膚疾患治療剤 |
US5958420A (en) | 1997-03-13 | 1999-09-28 | Nortrade Medical, Inc. | Treatment of burns, cuts, and abrasions of the skin |
US20030190339A1 (en) | 1997-10-14 | 2003-10-09 | Gregory Skover | Novel skin resurfacing recovery system |
DE10017530A1 (de) * | 2000-04-10 | 2001-10-18 | Suwelack Skin & Health Care Ag | Maske aus flexiblen, zur Flüssigkeitsaufnahme geeigneten Träger, Pflegeset enthaltend diese Maske, Verfahren zur Herstellung einer Maske sowie Verfahren zur kosmetischen Behandlung unter Verwendung dieser Maske |
US6702792B2 (en) * | 2002-07-18 | 2004-03-09 | Kenji Nakamura | Face mask having excellent usability |
DE10323794A1 (de) | 2003-05-23 | 2004-12-09 | Dr. Suwelack Skin & Health Care Ag | Verfahren zur Herstellung von Alginat-haltigen porösen Formkörpern |
DE10350654A1 (de) | 2003-10-29 | 2005-06-02 | Dr. Suwelack Skin & Health Care Ag | Collagen-Träger-Wirkstoff-Zusammensetzung |
DE102004025495A1 (de) | 2004-05-21 | 2005-12-15 | Dr. Suwelack Skin & Health Care Ag | Verfahren zur Herstellung von Alginat-haltigen porösen Formkörpern |
DE102006038629A1 (de) | 2006-08-17 | 2008-02-21 | Dr. Suwelack Skin & Health Care Ag | Stabilisierte Wirkstoffzusammensetzung |
-
2010
- 2010-03-31 EP EP10158628.7A patent/EP2371237B1/fr active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2743916C1 (ru) * | 2020-07-28 | 2021-03-01 | Владимир Николаевич Школьный | Маска косметическая сегментированная однократного применения |
DE202022106557U1 (de) | 2022-11-23 | 2022-12-02 | Elena Berkana | Netz-Gesichtsmaske |
Also Published As
Publication number | Publication date |
---|---|
EP2371237A1 (fr) | 2011-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2394617B1 (fr) | Biomatrices perforées en forme de couches | |
EP1749047B1 (fr) | Procede pour fabriquer des elements moules poreux a base d'alginate | |
EP2253665B1 (fr) | Composition lyophilisée | |
EP2218447A1 (fr) | Compositions contenant des micro ou nanoparticules lipides pour l'amélioration de l'action dermique de particules solides | |
DE10034491A1 (de) | Folien-Dermatika | |
EP2460531B1 (fr) | Collagène pour l'utilisation dans le traitement de maladies de la peau | |
JP2009541301A (ja) | 集中ケア及び全体的トリートメントを同時に送達することができるトリートメント物品 | |
DE10226990A1 (de) | Topisch applizierbare Mikro-Emulsionen mit binärer Phasen- und Wirkstoffdifferenzierbarkeit, deren Herstellung und deren Verwendung, insbesondere zur Versorgung der Haut mit bioverfügbarem Sauerstoff | |
KR20090083750A (ko) | 피부 가용성 터치 필름 | |
EP3634342A1 (fr) | Coussinet en silicone comprenant des principes actifs pour les soins de la peau et contre le vieillissement de la peau | |
DE19911262C2 (de) | Vorrichtung zur Abgabe kosmetischer Wirkstoffe | |
EP2371237B1 (fr) | Masque facial | |
EP3666259A1 (fr) | Compositions aqueuses capables de mousser a base de biopolymeres avec une distribution de cellulures memoire de gas flexible selon son usage | |
KR101795709B1 (ko) | 피부 온도 감응형 기능성 하이드로 겔을 이용한 얼굴윤곽 개선용 패치 및 그 제조방법 | |
US20060067996A1 (en) | Preventing/treating signs of skin stress/aging by bioenergetically modifying acupuncture points of the face or neck | |
EP1551373B1 (fr) | Utilisation d'elements moules pour une application externe | |
WO2009115216A1 (fr) | Utilisation d'un constituant ou d'un extrait de baobab en cas de maladies de peau | |
DE202022106557U1 (de) | Netz-Gesichtsmaske | |
CN106860188A (zh) | 美容润肤纳米乳霜 | |
EP2399648B1 (fr) | Composition cosmétique et son utilisation | |
DE202006019185U1 (de) | Feuchtigkeitsspendendes, wasserhaltiges Sanddorn-Hautpflegepräparat | |
DE102012014688A1 (de) | Chitosan-Präparat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA ME RS |
|
17P | Request for examination filed |
Effective date: 20120307 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MEDSKIN SOLUTIONS DR. SUWELACK AG |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150305 |
|
INTG | Intention to grant announced |
Effective date: 20150311 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
INTG | Intention to grant announced |
Effective date: 20150709 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 744614 Country of ref document: AT Kind code of ref document: T Effective date: 20150915 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: GERMAN |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 502010010138 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: LATSCHA SCHOELLHORN PARTNER AG, CH |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151127 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151126 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20150826 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151228 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151226 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 502010010138 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20160530 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160331 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20170322 Year of fee payment: 8 Ref country code: IE Payment date: 20170323 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20100331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150826 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: GRELLINGERSTRASSE 60, 4052 BASEL (CH) |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 744614 Country of ref document: AT Kind code of ref document: T Effective date: 20180331 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180331 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180331 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20230428 Year of fee payment: 14 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20231123 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 502010010138 Country of ref document: DE Representative=s name: BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBB -, DE |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240331 Year of fee payment: 15 Ref country code: GB Payment date: 20240322 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240319 Year of fee payment: 15 |